Scott Dunseth Myers Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading activity

Scott Dunseth Myers is Director of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 338,795 shares of ZNTL, which is worth approximately $498,028. The most recent transaction as insider was on Jun 17, 2025, when has been sold 57,603 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 339K

30.21% 3M change

n/a 12M change

Total Value Held $498,028

Scott Dunseth Myers Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 17 2025	BUY Grant, award, or other acquisition	-	57,603 Added 14.53%	338,795 Common Stock
Apr 30 2025	BUY Open market or private purchase	$29,399 $1.4 p/Share	21,000 Added 6.95%	281,192 Common Stock
Nov 13 2024	BUY Grant, award, or other acquisition	-	260,192 Added 50.0%	260,192 Common Stock

Also insider at

AMAG

AMAG PHARMACEUTICALS, INC.

President & CEO

SELB

SELECTA BIOSCIENCES INC Healthcare

Director

HARP

Harpoon Therapeutics, Inc. Healthcare

DVAX

DYNAVAX TECHNOLOGIES CORP Healthcare

Director

VRDN

Viridian Therapeutics, Inc.\DE Healthcare

Chief Executive Officer

SDM